#1 Startup Dataset
Growth rates, revenue data, direct competitors and contact details.
David Rabuka Email
Founder, CEO, & President . Acrigen Biosciences
How to contact David Rabuka
Join and see David's contact info for free!Current Roles
Employees:
12Revenue:
$1.9MAbout
Acrigen Biosciences is an early-stage biotech company developing technologies to improve the efficiency and enhance the safety of CRISPR-Cas based gene editing. CRISPR-Cas system which enables the precise enzymatic editing of genes is one of the most exciting and promising techniques to be developed in the last few years with the capability to prevent or cure many devastating diseases. The current challenge is to optimize the gene editing process to eliminates unwanted side effects and unanticipated editing in a patient. Acrigen Biosciences technology is based on a class of proteins, anti-CRISPR or Acr proteins, that precisely deactivate the Cas proteins serving as a gene editing “off switchâ€. The company is co-founded by Professor Joseph Bondy-Denomy, currently at UCSF, who discovered Acr proteins. Acrigen Biosciences is the first company developing Acr proteins to better control the CRISPR-Cas gene editing process to create an improved CRISPR gene editing platform for safe and effective gene therapies.Acrigen Biosciences Address
626 Bancroft WayBerkeley, CA
United States